MétaCan
Menu
Back to cohort
Record W4384070005 · doi:10.1093/noajnl/vdad071.007

INTERCEPTING BRAIN METASTASES THROUGH METABOLIC VULNERABILITIES

2023· article· en· W4384070005 on OpenAlexaff
Agata Kieliszek, Daniel Mobilio, Blessing Bassey‐Archibong, Jarrod W. Johnson, Michael Piotrowski, Najaf Aghaei, William D. Gwynne, Luis M. Escudero, Susan Chafe, Karen Zhang, Andrew T. Quaile, Dillon McKenna, Minomi Subapanditha, Elvin D. de Araujo, A Sedighi, Patrick T. Gunning, Tomáš Tokár, Chitra Venugopal, J. Rafael Montenegro-Burke, Jakob Magolan, Sheila K. Singh

Bibliographic record

VenueNeuro-Oncology Advances · 2023
Typearticle
Languageen
FieldMedicine
TopicBrain Metastases and Treatment
Canadian institutionsMcMaster University
FundersBrain Tumor Funders' Collaborative
KeywordsIn vivoTranscriptomePopulationMedicineCancer researchIn vitroBioinformaticsPharmacologyOncologyBiologyGeneGene expression

Abstract

fetched live from OpenAlex

Abstract BTFC travel award recipient Patients with brain metastases (BM) face a 90% mortality rate within one year of diagnosis because the current standard of care is mainly palliative. Our patient-derived xenograft models have successfully recapitulated all the stages of the metastatic cascade and captured a “premetastatic” population of BM cells that have just seeded the brains of mice before forming mature, clinically detectable tumors. We applied RNA sequencing of premetastatic BM cells to reveal a unique deregulated transcriptomic profile that is specific to premetastatic cells despite the tumor of origin. Subsequent Connectivity Map analysis led us to identify a tool compound that exhibits anti-BM activity in vitro, while remaining ineffective against normal brain cell controls. Follow up preclinical studies showed that treatment with this tool compound reduces the tumor burden of mice compared to placebo, while providing a significant survival advantage. Mass spectrometry-based metabolomics and CRISPR knock-out studies directly validated our tool compound’s target as a targetable therapeutic vulnerability in BM, where pharmacological and genetic perturbation of the target attenuates BM cell proliferation both in vitro and in vivo. We have now begun a large-scale medicinal chemistry campaign to develop novel, brain penetrant inhibitors of this target with drug-like pre-clinical profiles validated by our in vivo experimental models for later stage preclinical development and subsequent clinical development. This potential first-in-class anti-metastatic therapy may provide an alternative treatment strategy for at-risk patients that are otherwise limited to palliation and could open the gate to future development of other anti-metastatic therapies.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.899
Threshold uncertainty score0.887

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.040
GPT teacher head0.367
Teacher spread0.327 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology AdvancesSame topicBrain Metastases and TreatmentFrench-language works237,207